search
Back to results

Medacta NextAR TKA Pivotal Trial

Primary Purpose

Musculoskeletal Diseases

Status
Recruiting
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
NextAR TKA system
Sponsored by
Medacta International SA
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Musculoskeletal Diseases focused on measuring total knee arthroplasty, surgical navigation, medially-stabilized TKA

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Males and females aged over 18 years at time of surgery.
  2. Patients who are scheduled to receive Medacta GMK® Sphere system for primary TKA (class III, CE-marked).
  3. Patients with functional contralateral knee (i.e. without the need to use walking aids).
  4. Patients willing and able to provide written informed consent for participation.
  5. Patients willing to comply with the pre and post-operative evaluation schedule.

Exclusion Criteria:

  1. Patients with one or more medical conditions identified as a contraindication defined by the labelling on any Medacta implants used in this study:

    • Patients presenting with progressive local or systemic infection
    • Muscular loss, neuromuscular disease or vascular deficiency of the affected limb, making the operation unjustifiable.
    • Severe instability secondary to advanced destruction of condralar structures or loss of integrity of the medial or lateral ligament
  2. Patients whose prospects for a recovery to independent mobility would be compromised by known coexistent, medical problems.
  3. Patients affected by concomitant spine, hip, ankle or contralateral knee pathologies that can affect walking capacity.
  4. Patients unable to understand and take action.
  5. Patients with known allergy to the materials used.
  6. Patients in which Medacta GMK® Sphere system is used in emergency interventions.

Sites / Locations

  • Privatklinik BelairRecruiting
  • Privatklinik LindbergRecruiting
  • Kantonsspital Winterthur
  • Uniklinik BalgristRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Single-arm

Arm Description

Patients suitable to receive Medacta GMK® Sphere system for primary TKA will be invited to take part to the study during the preoperative visit. Follow-ups are performed after 2, 6 and 12 months. Data collection includes clinical and radiological data for preoperative and postoperative assessments, as well as intraoperative details.

Outcomes

Primary Outcome Measures

Functional outcome
Oxford Knee Score (OKS)

Secondary Outcome Measures

Functional outcome
Oxford Knee Score (OKS)
Functional outcome
Forgotten Joint Score (FJS)
Clinical and functional outcome
Knee Society Score (KSS)
Radiological outcomes
Radiological assessment including implant positioning, presence of radiolucent lines, subsidence, migration of components, presence of heterotopic ossifications or osteolysis
Surgical outcome - Surgical time
Surgical time (min)
Surgical outcome - Necessity of soft tissue release
Necessity of soft tissue release to obtain ligament or patellar balance (Y/N)
Surgical outcome -Time to discharge
Time to discharge (days)
Safety outcomes
Device deficiencies and adverse events

Full Information

First Posted
April 8, 2021
Last Updated
March 15, 2023
Sponsor
Medacta International SA
search

1. Study Identification

Unique Protocol Identification Number
NCT04844879
Brief Title
Medacta NextAR TKA Pivotal Trial
Official Title
Prospective, Multicentre, Single-arm, Open, Confirmatory Trial to Assess Efficacy and Safety of a Navigation System Providing Personalized Soft Tissue Balance Data in Medially-stabilized Total Knee Arthroplasty
Study Type
Interventional

2. Study Status

Record Verification Date
December 2022
Overall Recruitment Status
Recruiting
Study Start Date
May 17, 2021 (Actual)
Primary Completion Date
April 30, 2024 (Anticipated)
Study Completion Date
April 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Medacta International SA

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The goal of this study is to assess the efficacy and safety of a navigation system providing personalized soft tissue balance data in medially-stabilized total knee arthroplasty (TKA).
Detailed Description
This is a prospective, multicentre, single-arm, open, confirmatory clinical investigation to assess the efficacy and safety of a navigation system providing personalized soft tissue balance data in medially-stabilized total knee arthroplasty (TKA). Participants will be informed about the study, both orally and in writing, during a preoperative visit. The investigator will answer any questions that may arise and will collect the informed consent. During the study, enrolled participants will be able to withdraw at any time and for any reason. The study is conducted according to the following schedule: V1 : Inclusion during a preoperative visit V2: Surgery V3: Follow-up visit at 2 month post-surgery V4: Follow-up visit at 6 months post-surgery V5: Follow-up visit at 12 months post-surgery The following data will be collected: Oxford Knee Score (OKS), Knee Society Score (KSS), Forgotten Joint Score (FJS) and patient satisfaction at 6 months and 12 months of follow-up; Radiological analysis at 2 and 12 months of follow-up; Surgical time (min); Necessity of soft tissue release to obtain ligament or patellar balance; Time to discharge (days); Device deficiencies and peri- and postoperative adverse events. A web-based data collection tool will be used as Electronic Data Capture (EDC). All the information required by the protocol will be collected in electronic case report forms (eCRF). The statistical analysis will be performed according to a pre-established statistical analysis plan. Missing values will not be replaced by estimated values but will be considered as missing in the statistical analysis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Musculoskeletal Diseases
Keywords
total knee arthroplasty, surgical navigation, medially-stabilized TKA

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
40 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Single-arm
Arm Type
Experimental
Arm Description
Patients suitable to receive Medacta GMK® Sphere system for primary TKA will be invited to take part to the study during the preoperative visit. Follow-ups are performed after 2, 6 and 12 months. Data collection includes clinical and radiological data for preoperative and postoperative assessments, as well as intraoperative details.
Intervention Type
Device
Intervention Name(s)
NextAR TKA system
Intervention Description
The NextAR TKA system is a surgical guidance system which measures intra-operatively the effect of prosthesis alignment and positioning on soft tissue balance.
Primary Outcome Measure Information:
Title
Functional outcome
Description
Oxford Knee Score (OKS)
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Functional outcome
Description
Oxford Knee Score (OKS)
Time Frame
12 months
Title
Functional outcome
Description
Forgotten Joint Score (FJS)
Time Frame
6 months and 12 months
Title
Clinical and functional outcome
Description
Knee Society Score (KSS)
Time Frame
6 months and 12 months
Title
Radiological outcomes
Description
Radiological assessment including implant positioning, presence of radiolucent lines, subsidence, migration of components, presence of heterotopic ossifications or osteolysis
Time Frame
2 months and 12 months
Title
Surgical outcome - Surgical time
Description
Surgical time (min)
Time Frame
Intraoperative
Title
Surgical outcome - Necessity of soft tissue release
Description
Necessity of soft tissue release to obtain ligament or patellar balance (Y/N)
Time Frame
Intraoperative
Title
Surgical outcome -Time to discharge
Description
Time to discharge (days)
Time Frame
2 months
Title
Safety outcomes
Description
Device deficiencies and adverse events
Time Frame
Intraoperative, 2 months, 6 months and 12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Males and females aged over 18 years at time of surgery. Patients who are scheduled to receive Medacta GMK® Sphere system for primary TKA (class III, CE-marked). Patients with functional contralateral knee (i.e. without the need to use walking aids). Patients willing and able to provide written informed consent for participation. Patients willing to comply with the pre and post-operative evaluation schedule. Exclusion Criteria: Patients with one or more medical conditions identified as a contraindication defined by the labelling on any Medacta implants used in this study: Patients presenting with progressive local or systemic infection Muscular loss, neuromuscular disease or vascular deficiency of the affected limb, making the operation unjustifiable. Severe instability secondary to advanced destruction of condralar structures or loss of integrity of the medial or lateral ligament Patients whose prospects for a recovery to independent mobility would be compromised by known coexistent, medical problems. Patients affected by concomitant spine, hip, ankle or contralateral knee pathologies that can affect walking capacity. Patients unable to understand and take action. Patients with known allergy to the materials used. Patients in which Medacta GMK® Sphere system is used in emergency interventions.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Marco Viganò, PhD
Phone
+41916966060
Email
m.vigano@medacta.ch
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sandro Fucentese, Prof. Dr. med.
Organizational Affiliation
Balgrist University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Privatklinik Belair
City
Schaffhausen
ZIP/Postal Code
8200
Country
Switzerland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Peter Koch, Dr. med.
Facility Name
Privatklinik Lindberg
City
Winterthur
ZIP/Postal Code
8400
Country
Switzerland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Peter Koch, Dr. med.
Facility Name
Kantonsspital Winterthur
City
Winterthur
ZIP/Postal Code
8401
Country
Switzerland
Individual Site Status
Active, not recruiting
Facility Name
Uniklinik Balgrist
City
Zurich
ZIP/Postal Code
8008
Country
Switzerland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sandro Fucentese, Prof. Dr. med.

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Medacta NextAR TKA Pivotal Trial

We'll reach out to this number within 24 hrs